<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23876" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Ketamine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rosenbaum</surname>
            <given-names>Steven B.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Vikas</given-names>
          </name>
          <aff>Wellness Psychiatry P.C</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Palacios </surname>
            <given-names>Jorge L.</given-names>
          </name>
          <aff>Kaweah Delta Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Steven Rosenbaum declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vikas Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jorge Palacios declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23876.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Ketamine hydrochloride, commonly known as ketamine, is a medication approved by the United States Food and Drug Administration (FDA) for use as a general anesthetic either on its own or in combination&#x000a0;with other medications. The medication is highly effective for brief medical procedures that do not necessitate skeletal muscle relaxation and can be utilized as a pre-anesthetic for the induction of general anesthesia when combined with other general anesthetic agents. Furthermore, ketamine is FDA-approved for enhancing the effects of low-potency substances such as nitrous oxide.</p>
        <p>In addition to its anesthetic applications, ketamine proves invaluable in pain management, addressing treatment-resistant depression, managing suicidal ideation, and treating refractory status epilepticus, with specific indications awaiting FDA approval.&#x000a0;The dosage determines the&#x000a0;application and resulting effects of the drug, leading to variations in the prescribing protocol. This versatility renders ketamine valuable in both anesthesia and pain management. Ongoing research explores the potential applications of ketamine in psychiatry across all isomeric forms.&#x000a0;At elevated doses, ketamine operates primarily as a sedative rather than an analgesic agent. This activity reviews ketamine's indications, mechanism of action, pharmacokinetics, adverse drug reactions, monitoring strategies, drug-drug interactions, and clinical toxicology for healthcare professionals to facilitate the enhancement of clinical best practice guidelines.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate indications for ketamine use, recognizing its role in general anesthesia, pain management, and potential applications in psychiatry.</p></list-item><list-item><p>Screen patients thoroughly, assessing their medical history and contraindications to determine suitability for ketamine administration.</p></list-item><list-item><p>Assess patients' responses to ketamine, adapting dosages and treatment plans based on individual needs and clinical outcomes.</p></list-item><list-item><p>Collaborate with interdisciplinary teams, sharing expertise on ketamine's diverse applications and contributing to comprehensive patient care plans.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23876&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23876">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23876.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Ketamine&#x000a0;hydrochloride,&#x000a0;commonly&#x000a0;known as ketamine, is a medication approved by the United States Food and Drug Administration (FDA) for use as a general anesthetic either on its own or in&#x000a0;combination&#x000a0;with other medications.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Ketamine is highly effective for brief medical procedures that do not necessitate skeletal muscle relaxation and can be utilized as a pre-anesthetic for the induction of general anesthesia when combined with other general anesthetic agents. Furthermore,&#x000a0;ketamine is FDA-approved for enhancing the effects of low-potency&#x000a0;substances such as&#x000a0;nitrous oxide.</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Ketamine is used in emergencies to provide short-term procedural sedation and rapid sequence intubation. The Society of Critical Care Medicine guidelines recognize ketamine as an effective medication for rapid sequence intubation.&#x000a0;The medication is preferred for patients with bronchospasm because of its bronchodilatory properties. Ketamine is used for procedures that require short-term sedation or anesthesia and can be safely used in a wide age range, starting from 3 months. Children metabolize ketamine faster than adults, so higher dosing is required. However, older patients are slow metabolizers and need lower dosing.</p>
        <p>A wealth of evidence&#x000a0;indicates the value of ketamine in treating severe pain, including conditions such as trauma, fractures, abdominal and flank pain, low back pain, and extremity pain. In addition to its anesthetic applications, ketamine proves invaluable in pain management, addressing treatment-resistant depression, managing suicidal ideation, and treating refractory status epilepticus, with specific indications awaiting FDA approval.&#x000a0;When used for pain management, sub-dissociative dosing, otherwise known as low-dose ketamine (LDK), is used either alone or as an adjunct to other pain relief medications. It is safe and effective to use in combination with injectable nonsteroidal pain medications as well as opioids. As concerns about opioid use have grown, it has become more widely accepted.<xref ref-type="bibr" rid="article-23876.r1">[1]</xref><xref ref-type="bibr" rid="article-23876.r2">[2]</xref>&#x000a0;The dosage determines the&#x000a0;application and resulting effects of the drug, leading to variations in the prescribing protocol. This versatility renders ketamine valuable in both anesthesia and pain management.</p>
        <p>Ongoing research explores&#x000a0;the&#x000a0;potential applications of&#x000a0;ketamine in psychiatry across all isomeric forms.&#x000a0;At elevated doses, ketamine operates primarily as a sedative rather than an analgesic agent.&#x000a0;Ketamine is also used successfully for treatment-resistant depression and suicidal ideation, although it is not yet FDA-approved.<xref ref-type="bibr" rid="article-23876.r3">[3]</xref>&#x000a0;</p>
        <p>Ketamine is a racemic mixture of both<italic toggle="yes">&#x000a0;</italic>(<italic toggle="yes">R</italic>)- and<italic toggle="yes">&#x000a0;</italic>(<italic toggle="yes">S</italic>)-enantiomers, whereas esketamine consists solely of the&#x000a0;(<italic toggle="yes">S</italic>)-enantiomer. The FDA has approved the esketamine for treatment-resistant depression in conjunction with another oral antidepressant.<xref ref-type="bibr" rid="article-23876.r4">[4]</xref>&#x000a0;Ketamine is also used in refractory status epilepticus.<xref ref-type="bibr" rid="article-23876.r5">[5]</xref><xref ref-type="bibr" rid="article-23876.r6">[6]</xref></p>
        <p>At doses below a certain threshold, ketamine produces analgesia and sedation. However, once the critical threshold of roughly 1 to 1.5 mg/kg intravenously (IV) or 3 to 4 mg/kg intramuscularly (IM) is reached, the characteristic dissociative state abruptly appears. The dissociative state is&#x000a0;inconsistent with the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) definitions of moderate sedation or deep sedation; therefore, ketamine must be considered from a different perspective than drugs with the classical sedation continuum as described in the&#x000a0;American Society of Anesthesiologists guidelines.<xref ref-type="bibr" rid="article-23876.r7">[7]</xref></p>
      </sec>
      <sec id="article-23876.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Ketamine hydrochloride is a nonbarbiturate dissociative anesthetic.&#x000a0;As&#x000a0;a cyclohexanone derivative, the drug rapidly acts and produces profound anesthesia and analgesia. Its chemical name is &#x000b1;)-2-(o-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride;&#x000a0;the structural formula is CHClNO. Ketamine is a noncompetitive <italic toggle="yes">N</italic>-methyl-D-aspartate (NMDA) and glutamate receptor antagonist that blocks HCN1 receptors. The unique dissociative action and partial agonism of opiate mu-receptors permit painful procedures in a consistent state of sedation and comfort.<xref ref-type="bibr" rid="article-23876.r8">[8]</xref><xref ref-type="bibr" rid="article-23876.r9">[9]</xref><xref ref-type="bibr" rid="article-23876.r10">[10]</xref>&#x000a0;&#x000a0;</p>
        <p>Ketamine's efficacy in chronic pain as an antidepressant far outlast the actual drug concentrations and is possibly mediated by a secondary increase in structural synaptic connectivity mediated by a neuronal response to the ketamine-induced "hyper-glutamatergic state." The <italic toggle="yes">N</italic>-methyl-D-aspartate (NMDA) receptor has a significant role in the etiology of depression. Ketamine, through its NMDA antagonistic action, works rapidly in controlling symptoms of depression and acute suicidal ideation. Ketamine can elevate the levels of glutamate in the brain, stimulating synaptogenesis and elevated levels of brain-derived neurotrophic factor (BDNF).<xref ref-type="bibr" rid="article-23876.r11">[11]</xref>&#x000a0;Ketamine may interact with the sigma receptors.<xref ref-type="bibr" rid="article-23876.r12">[12]</xref>&#x000a0;It works by decreasing central sensitization, wind-up phenomenon (development of ongoing, worsening, or chronic pain), and pain memory. Cholinergic, monoaminergic, and opioid systems seem to play both a positive and negative modulatory function in both analgesia and sedation. Ketamine reverses tolerance to opioids.<xref ref-type="bibr" rid="article-23876.r13">[13]</xref><xref ref-type="bibr" rid="article-23876.r14">[14]</xref></p>
        <p>Ketamine generally maintains normal pharyngeal and laryngeal reflexes and permits spontaneous respiration. It enhances or maintains normal skeletal muscle tone and is associated with cardiovascular and respiratory stimulation.<xref ref-type="bibr" rid="article-23876.r15">[15]</xref>&#x000a0;These characteristics make it particularly useful in the emergency department for short-term procedures, especially&#x000a0;if a patient&#x000a0;is unprepared for an emergency procedure. Since no guarantee of maintenance of the pharyngeal and laryngeal reflexes is apparent, no assumption of airway protection can exist. Additionally, transient minimal respiratory depression may exist if the medication is administered too rapidly or at too high a dose. Therefore, the&#x000a0;clinician&#x000a0;should be ready to perform emergency intubation.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Ketamine administered IV exhibits a rapid onset of action, achieving peak plasma concentrations quickly. The IM route of administration provides a high bioavailability of 93% and results in peak plasma levels within 5 to 30 minutes. However, oral ketamine has a significantly lower bioavailability of around 16% to 29% due to extensive first-pass hepatic metabolism. In contrast, intranasal and intrarectal administration of ketamine has demonstrated better bioavailability at 45% to 50% and 25% to 30%, respectively.<xref ref-type="bibr" rid="article-23876.r16">[16]</xref></p>
        <p><bold>Metabolism:</bold> Ketamine is primarily metabolized by the enzymes CYP3A4 and, secondarily, the enzymes CYP2B6 and CYP2C9.<xref ref-type="bibr" rid="article-23876.r17">[17]</xref><xref ref-type="bibr" rid="article-23876.r18">[18]</xref>&#x000a0;It undergoes N-dealkylation, hydroxylation, conjugation, and dehydration.</p>
        <p><bold>Distribution:</bold> Ketamine quickly enters the brain. It has a plasma protein binding from 10% to 50%. The steady-state volume of distribution is 3 to 5 L/kg.</p>
        <p><bold>Elimination:</bold> Following&#x000a0;IV administration, ketamine redistributes from the CNS to peripheral tissues. Its elimination half-life is typically 2 to 4 hours. After administration, most ketamine and metabolites are excreted through urine, with 91% of administered radioactivity appearing over&#x000a0;5 days. Only about 20% occur as the parent drug or major metabolites. Additionally, hydroxylated metabolites of ketamine and nor-ketamine are eliminated in urine and bile.<xref ref-type="bibr" rid="article-23876.r19">[19]</xref></p>
      </sec>
      <sec id="article-23876.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Ketamine is usually administered either&#x000a0;IV or IM. The available strengths include 200 mg/20 mL (10 mg/mL), 500 mg/5 mL (100 mg/mL), and 500 mg/10 mL (50 mg/mL). It is essential to dilute ketamine with an equal volume of normal saline, sterile water, or 5% dextrose.&#x000a0;</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Dosing varies according to the desired effect, the patient's age, and underlying conditions. When using larger total doses of ketamine, administering it more rapidly than normal, or using ketamine with sedatives, barbiturates, or narcotics, exaggerated responses may occur, and prolonged recovery times should be expected.<xref ref-type="bibr" rid="article-23876.r20">[20]</xref><xref ref-type="bibr" rid="article-23876.r21">[21]</xref>&#x000a0;The recommended initial IV dosage of ketamine falls within the range of 1 to 4.5 mg/kg (0.5 to 2 mg/lb) administered over 60 seconds for individuals aged 16 years and above. An average dose of 2 mg/kg (1 mg/lb) is typically needed to induce around 5 to 10 minutes of anesthesia or dissociative effects. The onset of action occurs within approximately 10 to 30 seconds, while the duration of action lasts about 5 to 15 minutes.</p>
        <p>Additional doses can be administered IV or IM to maintain anesthesia without producing cumulative effects for more prolonged anesthesia. Either one-half or additional doses may be repeated as needed. Dosing adjustments will be required if used in combination with other drugs, such as IV benzodiazepines or narcotics. When using diazepam in adults, maintenance should be via slow infusion at 0.1 to 0.5 mg/minute of ketamine. Additional doses of diazepam in the amount of 2 to 5 mg are an option. Tonic-clonic movements may present during the emergence of ketamine. These movements do not&#x000a0;indicate&#x000a0;additional doses of the anesthetic are required.<xref ref-type="bibr" rid="article-23876.r22">[22]</xref>&#x000a0;</p>
        <p>An alternative induction dose in adults is 1 to 2 mg/kg IV at a 0.5 mg/kg/min rate. IV diazepam 2 to 5 mg can be given over 60 seconds to reduce emergence phenomena. In most cases, 15 mg IV or less will suffice. The initial IM dose of ketamine ranges from 6.5 to 13 mg/kg (3 to 6 mg/lb). A 10 mg/kg (5 mg/lb) dose usually produces 12 to 30 minutes of surgical anesthesia with an onset of action in 3 to 5 minutes. Sub-dissociative dosing (low-dose ketamine) is administered at 0.1 to 0.4 mg/kg IV.<xref ref-type="bibr" rid="article-23876.r23">[23]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> No dosage adjustments are provided in the FDA&#x000a0;recommendations; use caution.</p>
        <p><bold>Renal impairment: </bold>No dosage adjustments are provided in the FDA&#x000a0;recommendations; use caution.</p>
        <p><bold>Pregnancy considerations: </bold>The FDA does not recommend ketamine use during pregnancy due to a lack of established safety. Animal data show that ketorolac may cause harm to the fetus; avoid use during pregnancy, labor, and delivery. The American College of Obstetricians and Gynecologists (ACOG) states that general anesthesia is rarely used during vaginal or cesarean delivery in current obstetrics except in emergencies or when neuraxial anesthesia is not feasible. However, ketamine or propofol can be used as an inducing agent when required.<xref ref-type="bibr" rid="article-23876.r24">[24]</xref></p>
        <p><bold>Breastfeeding considerations: </bold>Use is not recommended&#x000a0;according to the FDA. However, limited clinical data suggest that ketamine and its metabolites are present in low concentrations in breast milk, and its low oral bioavailability implies a minimal risk to infants. The use of ketamine in nursing mothers does not affect lactation. Ketamine should be used with clinical monitoring of the infant.<xref ref-type="bibr" rid="article-23876.r25">[25]</xref></p>
        <p><bold>Pediatric patients: </bold>Children metabolize the ketamine more rapidly than adults and may require higher or additional dosing. In children, the IM dosing range is from 9 to 13 mg/kg (4 to 6 mg/lb) and usually produces surgical anesthesia within 3 minutes to 4 minutes following injection.</p>
        <p><bold>Older patients: </bold>Older patients metabolize ketamine slowly and may need lower dosing. A recent randomized controlled trial demonstrated promising results of ketamine for treatment-resistant depression.<xref ref-type="bibr" rid="article-23876.r26">[26]</xref></p>
      </sec>
      <sec id="article-23876.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse drug reactions associated with ketamine are nausea, vomiting, dizziness, diplopia, drowsiness, dysphoria, and confusion. Reports of the emergence phenomenon&#x000a0;exist for approximately 6% to 12% of patients. The common adverse drug reactions of ketamine are listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Allergic: anaphylaxis and angioedema.<xref ref-type="bibr" rid="article-23876.r27">[27]</xref><xref ref-type="bibr" rid="article-23876.r28">[28]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cardiovascular: Transient increases in blood pressure, bradycardia, left ventricular dysfunction in patients with heart failure, respiratory and cardiac arrest, and arrhythmias.<xref ref-type="bibr" rid="article-23876.r29">[29]</xref><xref ref-type="bibr" rid="article-23876.r30">[30]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Gastrointestinal: Anorexia, nausea, and vomiting.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Muscular: Muscle stiffness and spasms or tonic-clonic movements resembling seizures, and enhanced skeletal muscle tone</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ophthalmologic: Diplopia, nystagmus, and increased intraocular pressure.<xref ref-type="bibr" rid="article-23876.r31">[31]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Psychiatric: Amnesia, anxiety, confusion, depression, disorientation, dysphoria, dissociative state, hallucinations, flashbacks, unusual thoughts, extreme fear, excitement, irrational behavior, and insomnia.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Respiratory: Apnea, increased laryngeal and tracheal secretions, laryngospasm, airway obstruction in infants (may not be drug-related), and respiratory depression.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Skin: Injection site reactions (infrequent), local pain, erythema, and morbilliform rash.<xref ref-type="bibr" rid="article-23876.r32">[32]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Neurologic: Confusion, emergence, delirium, seizures, and hallucinations.<xref ref-type="bibr" rid="article-23876.r33">[33]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Central nervous system (CNS) depressants: Coadministration of ketamine with opioid analgesics, benzodiazepines, or CNS depressants, including alcohol, may induce profound sedation, respiratory depression, coma, and potentially fatal outcomes. Careful monitoring of neurological status and respiratory parameters, such as respiratory rate and pulse oximetry, is essential when combining ketamine with these agents. Consider personalized dose adjustments based on the patient's clinical condition.<xref ref-type="bibr" rid="article-23876.r34">[34]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sympathomimetic medications: Vasopressin and sympathomimetic medications may increase ketamine's sympathomimetic effects. Simultaneous use of MAO inhibitors with ketamine is contraindicated.<xref ref-type="bibr" rid="article-23876.r35">[35]</xref>&#x000a0;Monitoring of vital signs is recommended when administering ketamine with sympathomimetics or vasopressin, with dose adjustments tailored to the patient's individual clinical needs.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Theophylline: Concurrent use of ketamine with theophylline or aminophylline could potentially reduce the seizure threshold. Alternative medications should be considered for patients&#x000a0;prescribed theophylline or aminophylline with ketamine.<xref ref-type="bibr" rid="article-23876.r36">[36]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23876.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Ketamine is contraindicated in patients with underlying conditions in which increased blood pressure would pose a risk of complications such as aortic dissection, uncontrolled hypertension, myocardial infarction, or aneurysms. It is contraindicated in those who have shown prior hypersensitivity; anaphylaxis and angioedema have been reported.<xref ref-type="bibr" rid="article-23876.r27">[27]</xref><xref ref-type="bibr" rid="article-23876.r28">[28]</xref></p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p><bold>Pregnancy and lactation:</bold> Ketamine is not recommended for use during obstetrics, pregnancy, or breastfeeding,&#x000a0;according to the FDA.</p>
        <p><bold>Schizophrenia:</bold> Use should be avoided in patients with schizophrenia due to the potential for exacerbating the underlying condition.<xref ref-type="bibr" rid="article-23876.r37">[37]</xref></p>
        <p><bold>Hemodynamic instability:</bold>&#x000a0;Increased blood pressure, heart rate, and cardiac index have been observed. Hypotension and bradycardia, arrhythmias, and cardiac decompensation have also been observed. During the administration of ketamine, it is important to monitor the patient's vital signs and cardiac function closely. Ketamine is contraindicated in patients at risk of significant hypertension.<xref ref-type="bibr" rid="article-23876.r38">[38]</xref></p>
        <p><bold>Intracranial hypertension:</bold>&#x000a0;Ketamine can increase cerebrospinal fluid pressure.&#x000a0;In patients with cerebrospinal fluid&#x000a0;(CSF)&#x000a0;elevations, the use of ketamine is controversial due to questionable elevations of intracranial pressure caused by ketamine. Some studies indicate that the concern for&#x000a0;CSF elevation with ketamine has been overstated. Kropf et al found similar hemodynamic properties compared with etomidate. New research suggests ketamine may improve cerebral perfusion pressure and have neuroprotective properties.<xref ref-type="bibr" rid="article-23876.r39">[39]</xref><xref ref-type="bibr" rid="article-23876.r40">[40]</xref></p>
        <p><bold>Pediatric neurotoxicity:</bold> Extended use of ketamine for over 3 hours in children &#x02264;3 years can lead to pediatric neurotoxicity, resulting in cognitive deficits. One of the possible mechanisms is&#x000a0;neuronal apoptosis by the blockade of NMDA receptors.<xref ref-type="bibr" rid="article-23876.r41">[41]</xref><xref ref-type="bibr" rid="article-23876.r42">[42]</xref></p>
        <p><bold>Emergence delirium:</bold> Emergence delirium may be reduced by decreasing the recommended dose of ketamine, using it in conjunction with benzodiazepines, and reducing verbal and tactile stimulation during the drug administration. If "emergence" occurs, a small hypnotic dose of a short-acting barbiturate or benzodiazepine is recommended to terminate the reaction.<xref ref-type="bibr" rid="article-23876.r43">[43]</xref>&#x000a0;Diazepam, 2 to 5 mg IV push given over 1 minute (15 mg or less in most cases), can reduce emergence phenomena. In a randomized controlled study of adult emergency department patients, Sener et al found a significant reduction&#x000a0;in the incidence of agitation when coadministering midazolam with ketamine for procedural sedation.<xref ref-type="bibr" rid="article-23876.r44">[44]</xref></p>
        <p><bold>Hepatotoxicity:</bold> The FDA has recently issued a warning regarding drug-induced liver injury associated with ketamine.&#x000a0;Chronic&#x000a0;ketamine administration is associated with hepatoxicity (cholestatic pattern). Biliary duct dilatation with or without biliary obstruction has also been reported with recurrent use (eg, misuse or supervised unapproved indications). Clinicians should obtain baseline liver function tests, such as alkaline phosphatase and gamma-glutamyl transferase, and monitor&#x000a0;liver function tests at periodic intervals.<xref ref-type="bibr" rid="article-23876.r45">[45]</xref></p>
      </sec>
      <sec id="article-23876.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The following vital signs should be monitored:&#x000a0;blood pressure, pulse, breathing, and oxygen saturation. Clinicians should be prepared for intubation. Neuropsychiatric function requires monitoring, and a patient must be at baseline before discharge from care. After a patient's return to baseline, another responsible adult should supervise the patient's discharge. Patients should not drive, use heavy machinery, or perform potentially hazardous activities for up to 24 hours following ketamine administration.</p>
        <p>Ketamine is a DEA Schedule III controlled substance.<xref ref-type="bibr" rid="article-23876.r46">[46]</xref>&#x000a0;Clinicians need to be vigilant for physical and psychological dependence and addiction when ketamine is used recreationally. Drug dependence and tolerance to ketamine may develop after prolonged use. Withdrawal symptoms may also occur if ketamine is stopped suddenly.<xref ref-type="bibr" rid="article-23876.r47">[47]</xref><xref ref-type="bibr" rid="article-23876.r48">[48]</xref></p>
      </sec>
      <sec id="article-23876.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Ketamine is potentially fatal in alcohol-intoxicated patients.&#x000a0;It has been used recreationally as a drug of abuse. The street name for ketamine is "K" or "Special K." Illicit use of ketamine includes snorting or inhalation, and it is ingestable in food or drinks. The recreational use of ketamine can lead to toxicity.<xref ref-type="bibr" rid="article-23876.r49">[49]</xref>&#x000a0;Ketamine overdose induces varying dose-dependent symptoms, notably altering consciousness and manifesting as sedation, impaired mental status, mydriasis, and hemodynamic compromise.&#x000a0;Accidental ingestion up to 10 times higher than the standard induction dose of ketamine has been reported. Overdose of ketamine did not result in systemic effects such as hemodynamic or central nervous system perturbations, except for prolonged awakening.<xref ref-type="bibr" rid="article-23876.r50">[50]</xref></p>
        <p>No antidote for ketamine is recognized. Treatment primarily involves supportive care and maintaining the airway, breathing, and circulation. Gastrointestinal decontamination with activated charcoal may be considered, while medications such as benzodiazepines, alpha-2 agonists, and anticholinergics assist in symptom management. Hydration with crystalloids can aid in managing hyperthermia and dehydration. Observation periods and continuous monitoring of post-symptom resolution are vital components of treatment.&#x000a0;Ketamine misuse in recreational settings, with multiple substances, is a significant health concern. A study has revealed that ketamine, when combined with other drugs, is a significant contributor to overdoses and fatalities. Specifically, ketamine was found to be involved in 79% of overdose cases and 89.1% of deaths related to co-ingestants. This suggests a strong correlation between ketamine use and adverse outcomes when combined with other substances.<xref ref-type="bibr" rid="article-23876.r51">[51]</xref></p>
      </sec>
      <sec id="article-23876.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Ketamine's primary use is by anesthesiologists, certified registered nurse anesthetists, dentists, emergency physicians, pain specialists, psychiatrists, and paramedics; these disciplines need to function as an interprofessional team to optimize the drug's effectiveness while minimizing the potential for adverse events. All&#x000a0;clinicians who administer&#x000a0;ketamine should&#x000a0;understand&#x000a0;the indications and contraindications.</p>
        <p>Nurses and pharmacists can play a crucial role during ordering and administration, guarding against improper dosing and checking for adverse events and drug interactions. <xref ref-type="bibr" rid="article-23876.r52">[52]</xref>&#x000a0;Resuscitative&#x000a0;equipment is imperative if intubation is required. Before discharge, the clinical team must record the patient's vitals.&#x000a0;Important&#x000a0;discharge education includes informing&#x000a0;patients not to drive, use heavy machinery, or perform potentially hazardous activities for 24 hours after the administration of ketamine.&#x000a0;Critical care supervision is necessary for patients&#x000a0;under mechanical ventilation.&#x000a0;An interprofessional team approach is necessary to improve patient outcomes related to ketamine and minimize adverse drug reactions.</p>
      </sec>
      <sec id="article-23876.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23876&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23876">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23876/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23876">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23876.s11">
        <title>References</title>
        <ref id="article-23876.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ternas</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Motov</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>The use of subdissociative-dose ketamine for acute pain in the emergency department.</article-title>
            <source>Acad Emerg Med</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>251</fpage>
            <page-range>251-7</page-range>
            <pub-id pub-id-type="pmid">25716117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lumanauw</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Youn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Horeczko</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tanen</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Subdissociative-dose Ketamine Is Effective for Treating Acute Exacerbations of Chronic Pain.</article-title>
            <source>Acad Emerg Med</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>26</volume>
            <issue>9</issue>
            <fpage>1044</fpage>
            <page-range>1044-1051</page-range>
            <pub-id pub-id-type="pmid">30901130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McIntyre</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Rosenblat</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Nemeroff</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Sanacora</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Murrough</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Berk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brietzke</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dodd</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gorwood</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Iosifescu</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Lopez Jaramillo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kratiuk</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lui</surname>
                <given-names>LMW</given-names>
              </name>
              <name>
                <surname>Mansur</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Papakostas</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Subramaniapillai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thase</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vieta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Zarate</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.</article-title>
            <source>Am J Psychiatry</source>
            <year>2021</year>
            <month>May</month>
            <day>01</day>
            <volume>178</volume>
            <issue>5</issue>
            <fpage>383</fpage>
            <page-range>383-399</page-range>
            <pub-id pub-id-type="pmid">33726522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swainson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Archer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chrenek</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>MacKay</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dursun</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Klassen</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Chokka</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Demas</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Esketamine for treatment resistant depression.</article-title>
            <source>Expert Rev Neurother</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>19</volume>
            <issue>10</issue>
            <fpage>899</fpage>
            <page-range>899-911</page-range>
            <pub-id pub-id-type="pmid">31282772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buratti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Giacheri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Palmieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tibaldi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brisca</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Riva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Striano</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mancardi</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Nobili</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moscatelli</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ketamine as advanced second-line treatment in benzodiazepine-refractory convulsive status epilepticus in children.</article-title>
            <source>Epilepsia</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>64</volume>
            <issue>4</issue>
            <fpage>797</fpage>
            <page-range>797-810</page-range>
            <pub-id pub-id-type="pmid">36792542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Legriel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oddo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brophy</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>What's new in refractory status epilepticus?</article-title>
            <source>Intensive Care Med</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>543</fpage>
            <page-range>543-546</page-range>
            <pub-id pub-id-type="pmid">27544138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <collab>American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists</collab>
            <article-title>Practice guidelines for sedation and analgesia by non-anesthesiologists.</article-title>
            <source>Anesthesiology</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>96</volume>
            <issue>4</issue>
            <fpage>1004</fpage>
            <page-range>1004-17</page-range>
            <pub-id pub-id-type="pmid">11964611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nichols</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Paciullo</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Subdissociative Ketamine Use in the Emergency Department.</article-title>
            <source>Adv Emerg Nurs J</source>
            <year>2019</year>
            <season>Jan/Mar</season>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-22</page-range>
            <pub-id pub-id-type="pmid">30702529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>BinKharfi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>AlSagre</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>BET 2: Safety and efficacy of low-dose ketamine versus opioids for acute pain management in the ED.</article-title>
            <source>Emerg Med J</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>128</fpage>
            <page-range>128-129</page-range>
            <pub-id pub-id-type="pmid">30696780</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kapur</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kapur</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Conscious Sedation in Dentistry.</article-title>
            <source>Ann Maxillofac Surg</source>
            <year>2018</year>
            <season>Jul-Dec</season>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>320</fpage>
            <page-range>320-323</page-range>
            <pub-id pub-id-type="pmid">30693254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zorumski</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Izumi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mennerick</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Ketamine: NMDA Receptors and Beyond.</article-title>
            <source>J Neurosci</source>
            <year>2016</year>
            <month>Nov</month>
            <day>02</day>
            <volume>36</volume>
            <issue>44</issue>
            <fpage>11158</fpage>
            <page-range>11158-11164</page-range>
            <pub-id pub-id-type="pmid">27807158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robson</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seminerio</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of sigma (&#x003c3;) receptors in the antidepressant-like effects of ketamine in vitro and in vivo.</article-title>
            <source>Eur Neuropsychopharmacol</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>308</fpage>
            <page-range>308-17</page-range>
            <pub-id pub-id-type="pmid">21911285</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mion</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Villevieille</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings).</article-title>
            <source>CNS Neurosci Ther</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>370</fpage>
            <page-range>370-80</page-range>
            <pub-id pub-id-type="pmid">23575437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mercadante</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Villari</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ferrera</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Burst ketamine to reverse opioid tolerance in cancer pain.</article-title>
            <source>J Pain Symptom Manage</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>302</fpage>
            <page-range>302-5</page-range>
            <pub-id pub-id-type="pmid">12691680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suleiman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Santer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Munoz-Acuna</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hammer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Wachtendorf</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Rumyantsev</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Berra</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chamadia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johnson-Akeju</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Baedorf-Kassis</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Eikermann</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effects of Ketamine Infusion on Breathing and Encephalography in Spontaneously Breathing ICU Patients.</article-title>
            <source>J Intensive Care Med</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>299</fpage>
            <page-range>299-306</page-range>
            <pub-id pub-id-type="pmid">35934953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zanos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Moaddel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Riggs</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Highland</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Georgiou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>EFR</given-names>
              </name>
              <name>
                <surname>Albuquerque</surname>
                <given-names>EX</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Zarate</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Gould</surname>
                <given-names>TD</given-names>
              </name>
            </person-group>
            <article-title>Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.</article-title>
            <source>Pharmacol Rev</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>70</volume>
            <issue>3</issue>
            <fpage>621</fpage>
            <page-range>621-660</page-range>
            <pub-id pub-id-type="pmid">29945898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andrade</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Ketamine for Depression, 5: Potential Pharmacokinetic and Pharmacodynamic Drug Interactions.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>78</volume>
            <issue>7</issue>
            <fpage>e858</fpage>
            <page-range>e858-e861</page-range>
            <pub-id pub-id-type="pmid">28858450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Langmia</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Just</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Yamoune</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Stingl</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Pharmacogenetic and drug interaction aspects on ketamine safety in its use as antidepressant - implications for precision dosing in a global perspective.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>88</volume>
            <issue>12</issue>
            <fpage>5149</fpage>
            <page-range>5149-5165</page-range>
            <pub-id pub-id-type="pmid">35863300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dinis-Oliveira</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Metabolism and metabolomics of ketamine: a toxicological approach.</article-title>
            <source>Forensic Sci Res</source>
            <year>2017</year>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-10</page-range>
            <pub-id pub-id-type="pmid">30483613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dadiomov</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The effects of ketamine on suicidality across various formulations and study settings.</article-title>
            <source>Ment Health Clin</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-60</page-range>
            <pub-id pub-id-type="pmid">30627504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brinck</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Tiippana</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Heesen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Straube</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Kontinen</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Perioperative intravenous ketamine for acute postoperative pain in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Dec</month>
            <day>20</day>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>CD012033</fpage>
            <pub-id pub-id-type="pmid">30570761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jolly</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>McLean</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Use of ketamine during procedural sedation: indications, controversies, and side effects.</article-title>
            <source>J Infus Nurs</source>
            <year>2012</year>
            <season>Nov-Dec</season>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>377</fpage>
            <page-range>377-82</page-range>
            <pub-id pub-id-type="pmid">23132086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Buvanendran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schwenk</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Wasan</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Hurley</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Viscusi</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Narouze</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>FN</given-names>
              </name>
              <name>
                <surname>Ritchie</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Lubenow</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Hooten</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.</article-title>
            <source>Reg Anesth Pain Med</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>43</volume>
            <issue>5</issue>
            <fpage>521</fpage>
            <page-range>521-546</page-range>
            <pub-id pub-id-type="pmid">29870458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <collab>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins&#x02014;Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 209: Obstetric Analgesia and Anesthesia.</article-title>
            <source>Obstet Gynecol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>133</volume>
            <issue>3</issue>
            <fpage>e208</fpage>
            <page-range>e208-e225</page-range>
            <pub-id pub-id-type="pmid">30801474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r25">
          <label>25</label>
          <element-citation publication-type="book">
            <chapter-title>Ketamine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>9</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">29999626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oughli</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Gebara</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ciarleglio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lavretsky</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Flint</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Farber</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Karp</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Mulsant</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Roose</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Butters</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lenze</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition.</article-title>
            <source>Am J Geriatr Psychiatry</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>210</fpage>
            <page-range>210-221</page-range>
            <pub-id pub-id-type="pmid">36529623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bylund</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Delahanty</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The Case of Ketamine Allergy.</article-title>
            <source>Clin Pract Cases Emerg Med</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>1</volume>
            <issue>4</issue>
            <fpage>323</fpage>
            <page-range>323-325</page-range>
            <pub-id pub-id-type="pmid">29849335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valadkhani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Radmard</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Saeedi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Farnia</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Acute Angioedema in a Patient Who Received Ketamine and Succinylcholine: A Case Report.</article-title>
            <source>Chin Med J (Engl)</source>
            <year>2016</year>
            <month>Sep</month>
            <day>20</day>
            <volume>129</volume>
            <issue>18</issue>
            <fpage>2264</fpage>
            <pub-id pub-id-type="pmid">27625106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>TSS</given-names>
              </name>
              <name>
                <surname>Elahi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cheney</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Ketamine-induced QTc interval prolongation.</article-title>
            <source>J Anaesthesiol Clin Pharmacol</source>
            <year>2017</year>
            <season>Jan-Mar</season>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>136</fpage>
            <page-range>136-138</page-range>
            <pub-id pub-id-type="pmid">28413297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Page</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>O'Bryant</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dow</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Ky</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Trupp</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Lindenfeld</surname>
                <given-names>J</given-names>
              </name>
              <collab>American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research</collab>
            </person-group>
            <article-title>Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association.</article-title>
            <source>Circulation</source>
            <year>2016</year>
            <month>Aug</month>
            <day>09</day>
            <volume>134</volume>
            <issue>6</issue>
            <fpage>e32</fpage>
            <page-range>e32-69</page-range>
            <pub-id pub-id-type="pmid">27400984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagdeve</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Yaddanapudi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pandav</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>The effect of different doses of ketamine on intraocular pressure in anesthetized children.</article-title>
            <source>J Pediatr Ophthalmol Strabismus</source>
            <year>2006</year>
            <season>Jul-Aug</season>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>219</fpage>
            <page-range>219-23</page-range>
            <pub-id pub-id-type="pmid">16915900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nguyen</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Allergic Reaction to Ketamine as Monotherapy for Procedural Sedation.</article-title>
            <source>J Emerg Med</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>562</fpage>
            <page-range>562-564</page-range>
            <pub-id pub-id-type="pmid">27769614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hughes</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Boncyk</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Culley</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Fleisher</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>McDonagh</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Gan</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>McEvoy</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>TE</given-names>
              </name>
              <collab>Perioperative Quality Initiative (POQI) 6 Workgroup</collab>
            </person-group>
            <article-title>American Society for Enhanced Recovery and Perioperative Quality Initiative Joint Consensus Statement on Postoperative Delirium Prevention.</article-title>
            <source>Anesth Analg</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>130</volume>
            <issue>6</issue>
            <fpage>1572</fpage>
            <page-range>1572-1590</page-range>
            <pub-id pub-id-type="pmid">32022748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kobayashi</surname>
                <given-names>NHC</given-names>
              </name>
              <name>
                <surname>Farias</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Luz</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Machado-Ferraro</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Concei&#x000e7;&#x000e3;o</surname>
                <given-names>BCD</given-names>
              </name>
              <name>
                <surname>Silveira</surname>
                <given-names>CCMD</given-names>
              </name>
              <name>
                <surname>Fernandes</surname>
                <given-names>LMP</given-names>
              </name>
              <name>
                <surname>Cart&#x000e1;genes</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>VMM</given-names>
              </name>
              <name>
                <surname>Fontes-J&#x000fa;nior</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Maia</surname>
                <given-names>CDSF</given-names>
              </name>
            </person-group>
            <article-title>Ketamine plus Alcohol: What We Know and What We Can Expect about This.</article-title>
            <source>Int J Mol Sci</source>
            <year>2022</year>
            <month>Jul</month>
            <day>15</day>
            <volume>23</volume>
            <issue>14</issue>
            <pub-id pub-id-type="pmid">35887148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katz</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Toprak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Sanacora</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ostroff</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: A letter to the editor.</article-title>
            <source>Gen Hosp Psychiatry</source>
            <year>2018</year>
            <season>Sep-Oct</season>
            <volume>54</volume>
            <fpage>62</fpage>
            <page-range>62-64</page-range>
            <pub-id pub-id-type="pmid">30100209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uemura</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yamashita</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kurokawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yagita</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>[Nonconvulsive Status Epilepticus Associated with Theophylline: A Case Report].</article-title>
            <source>Brain Nerve</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>73</volume>
            <issue>3</issue>
            <fpage>283</fpage>
            <page-range>283-288</page-range>
            <pub-id pub-id-type="pmid">33678620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beck</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hindley</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Borgan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ginestet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McCutcheon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brugger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Driesen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ranganathan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D'Souza</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krystal</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Howes</surname>
                <given-names>OD</given-names>
              </name>
            </person-group>
            <article-title>Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia: A Systematic Review and Meta-analysis.</article-title>
            <source>JAMA Netw Open</source>
            <year>2020</year>
            <month>May</month>
            <day>01</day>
            <volume>3</volume>
            <issue>5</issue>
            <fpage>e204693</fpage>
            <pub-id pub-id-type="pmid">32437573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Groth</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Droege</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Connor</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Kaukeinen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Acquisto</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Chui</surname>
                <given-names>SHJ</given-names>
              </name>
              <name>
                <surname>Cucci</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Dixit</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Flannery</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Gustafson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Glass</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Horng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Heavner</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Kinney</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kruer</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Peppard</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Sarangarm</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sikora</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Viswesh</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Erstad</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Multicenter Retrospective Review of Ketamine Use in the ICU.</article-title>
            <source>Crit Care Explor</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>e0633</fpage>
            <pub-id pub-id-type="pmid">35187497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gregers</surname>
                <given-names>MCT</given-names>
              </name>
              <name>
                <surname>Mikkelsen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lindvig</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Br&#x000f8;chner</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Ketamine as an Anesthetic for Patients with Acute Brain Injury: A Systematic Review.</article-title>
            <source>Neurocrit Care</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>273</fpage>
            <page-range>273-282</page-range>
            <pub-id pub-id-type="pmid">32328972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Ketamine does not increase intracranial pressure compared with opioids: meta-analysis of randomized controlled trials.</article-title>
            <source>J Anesth</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>28</volume>
            <issue>6</issue>
            <fpage>821</fpage>
            <page-range>821-7</page-range>
            <pub-id pub-id-type="pmid">24859931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dong</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Anand</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Developmental neurotoxicity of ketamine in pediatric clinical use.</article-title>
            <source>Toxicol Lett</source>
            <year>2013</year>
            <month>Jun</month>
            <day>20</day>
            <volume>220</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-60</page-range>
            <pub-id pub-id-type="pmid">23566897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalopita</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Armakolas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Philippou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zarros</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Angelogianni</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Ketamine-induced neurotoxicity in neurodevelopment: A synopsis of main pathways based on recent <italic>in vivo</italic> experimental findings.</article-title>
            <source>J Anaesthesiol Clin Pharmacol</source>
            <year>2021</year>
            <season>Jan-Mar</season>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-42</page-range>
            <pub-id pub-id-type="pmid">34103820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cherng</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Ketamine-induced emergence reactions after desflurane anaesthesia.</article-title>
            <source>Eur J Anaesthesiol</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>200</fpage>
            <page-range>200-1</page-range>
            <pub-id pub-id-type="pmid">17038218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sener</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eken</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schultz</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Serinken</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ozsarac</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Ketamine with and without midazolam for emergency department sedation in adults: a randomized controlled trial.</article-title>
            <source>Ann Emerg Med</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>57</volume>
            <issue>2</issue>
            <fpage>109</fpage>
            <page-range>109-114.e2</page-range>
            <pub-id pub-id-type="pmid">20970888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r45">
          <label>45</label>
          <element-citation publication-type="book">
            <chapter-title>Ketamine</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>4</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">31643659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Var&#x000ec;</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Ricci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cavallo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pichini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sirignano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Graziano</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Ketamine: From Prescription Anaesthetic to a New Psychoactive Substance.</article-title>
            <source>Curr Pharm Des</source>
            <year>2022</year>
            <volume>28</volume>
            <issue>15</issue>
            <fpage>1213</fpage>
            <page-range>1213-1220</page-range>
            <pub-id pub-id-type="pmid">35538799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Le</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Cordero</surname>
                <given-names>IP</given-names>
              </name>
              <name>
                <surname>Jawad</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Swainson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Di Vincenzo</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Jaberi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Phan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lui</surname>
                <given-names>LMW</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rosenblat</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>McIntyre</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>The abuse liability of ketamine: A scoping review of preclinical and clinical studies.</article-title>
            <source>J Psychiatr Res</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>151</volume>
            <fpage>476</fpage>
            <page-range>476-496</page-range>
            <pub-id pub-id-type="pmid">35623124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roxas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ahuja</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Isom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Capurso</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>A Potential Case of Acute Ketamine Withdrawal: Clinical Implications for the Treatment of Refractory Depression.</article-title>
            <source>Am J Psychiatry</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>178</volume>
            <issue>7</issue>
            <fpage>588</fpage>
            <page-range>588-591</page-range>
            <pub-id pub-id-type="pmid">34270337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Stories of Special K patients.</article-title>
            <source>J Thorac Dis</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>E37</fpage>
            <page-range>E37-8</page-range>
            <pub-id pub-id-type="pmid">24688784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warner</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Smischney</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Accidental Ketamine Overdose on Induction of General Anesthesia.</article-title>
            <source>Am J Case Rep</source>
            <year>2018</year>
            <month>Jan</month>
            <day>03</day>
            <volume>19</volume>
            <fpage>10</fpage>
            <page-range>10-12</page-range>
            <pub-id pub-id-type="pmid">29295971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chaves</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Wilffert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sanchez</surname>
                <given-names>ZM</given-names>
              </name>
            </person-group>
            <article-title>Overdoses and deaths related to the use of ketamine and its analogues: a systematic review.</article-title>
            <source>Am J Drug Alcohol Abuse</source>
            <year>2023</year>
            <month>Mar</month>
            <day>04</day>
            <volume>49</volume>
            <issue>2</issue>
            <fpage>141</fpage>
            <page-range>141-150</page-range>
            <pub-id pub-id-type="pmid">36410032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23876.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Salazar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amato</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Volk</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Schiff</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Using drug knowledgebase information to distinguish between look-alike-sound-alike drugs.</article-title>
            <source>J Am Med Inform Assoc</source>
            <year>2018</year>
            <month>Jul</month>
            <day>01</day>
            <volume>25</volume>
            <issue>7</issue>
            <fpage>872</fpage>
            <page-range>872-884</page-range>
            <pub-id pub-id-type="pmid">29800453</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
